Healthcare's Biggest Paperwork Nightmare Just Met AI

Billions vanish in the paperwork wars. One quiet company cashes in every time.

August 05, 2026

Ever fought a health insurer over a denied claim? Then you already get this business model. Hospitals lose billions every year to claims that get bounced, denied, or delayed.

The Wealth Strategy (Sponsored)

His official salary? $400,000 a year.

Yet his returns point to something far bigger: Up to $250,000 per month… from just one place.

It’s not property. It’s not equities.

So what’s really generating this kind of income — and why is it gaining traction now?

A healthcare software company just raised full-year guidance, and the AI cross-sell tailwind from its latest acquisition is barely getting started. Sell-side coverage is still thin.

The setup into Q3 looks tight, and this is the kind of name you want on the watchlist before analysts wake up and re-rate it.

Waystar Holding (NASDAQ: WAY) sells the software hospitals use to actually get paid. Q2 2026 just printed. Management raised full-year revenue guidance and leaned hard into AI-driven products and cross-sell from its Iodine acquisition.

What you're underappreciating is how much of the Iodine integration runway is still ahead.

Action: Accumulate on any pullback between now and the Q3 print. Add on strength if the cross-sell numbers keep landing.

What Just Happened

The Q2 report was the kind of print you want to see before you buy. Revenue grew comfortably ahead of expectations, and management raised full-year revenue outlook, calling out AI-driven solutions and Iodine cross-sell as the two things pulling numbers higher.

That's not a one-off. Two of the most durable trends in healthcare, hospitals squeezing every dollar out of their revenue cycles and payers using AI to deny more claims, both push demand for what Waystar sells. The company isn't riding a fad. It's selling a fix to a problem that gets worse every year.

See Why (Sponsored)

Elon Musk is now paying you 15X more than your bank…

Thanks to a project he's been working on for the last 27 years.

All you have to do is sign up for his new bank. 

For years, America's biggest banks have been telling you they have no choice but to pay you interest rates as low as 0.4% (that's the national average).

Now, suddenly… Elon is exposing many of these bankers for the sharks they really are. He's not offering double… or triple… or even five times the interest…

But 15 times the national average — at 6% per year.

This is just one of the radical ways Elon's new bank is disrupting the financial sector… 

Luke Lango is revealing how it could impact your money (and how you should prepare) here.

This ad is sent on behalf of InvestorPlace Media at 1125 N. Charles Street, Baltimore, Maryland 21201. If you're not interested in this opportunity, please click here.

What the Business Actually Does

Waystar builds the software that sits between hospitals and health insurers. A patient walks into a clinic, gets treated, and the bill has to travel through a maze of insurance forms, prior authorizations, and coding. That's the plumbing Waystar owns. Its platform automates claim submission, denials management, prior authorization, and patient billing.

The Iodine acquisition added mid-revenue-cycle intelligence, which is jargon for AI that helps hospitals document care correctly the first time so claims don't get bounced. Own the tools that both prevent denials and appeal them, and you own a very sticky piece of hospital IT. That's the moat.

AI reset (Sponsored)

Some AI stocks have captured most of the headlines—but one veteran analyst believes the next opportunities may lie elsewhere.

In his latest free briefing, he shares a simple "Sell This, Buy That" strategy, along with a Hotlist and Hitlist of stocks he's watching as the AI landscape continues to evolve.

Get the Free Hotlist

Why the Market Cares Again

AI is finally solving real problems in healthcare. Most of the AI-in-medicine buzz has been about drug discovery, but revenue cycle management is where AI is actually cutting costs today. Waystar's models learn from millions of claims, so every denial makes the next submission smarter. That's a data flywheel most competitors can't match.

Hospital margins are still under pressure. Nonprofit hospital margins are barely above breakeven in a lot of systems. When your hospital is scraping for basis points, revenue cycle software with measurable ROI is one of the last budget lines you'll see cut. If anything, RCM budgets are growing.

Iodine cross-sell is the real catalyst. Management called out cross-sell activity following the Iodine deal on the Q2 call, and this is what you want to hear. Selling more products into existing customers is the highest-margin growth a software company can print, and Waystar just added a big new SKU to the shelf.

What the Financials Are Signaling

Raised full-year revenue outlook. A guidance raise coming out of Q2 tells you management sees the pipeline getting stronger, not weaker. When healthcare software companies raise mid-year, it's usually because bookings visibility improved, not a one-time bump.

Free cash flow trajectory. Waystar's been building toward a real FCF story, with software-grade gross margins and a rising share of subscription revenue. Direction matters here, and it's pointing up.

Cross-sell driving net revenue retention. Iodine synergies feed directly into NRR. If NRR ticks meaningfully higher over the next two quarters, you'll see the market pay for it in the multiple, not just the earnings line.

Action: Watch NRR and Iodine attach rates on the Q3 call. Those two data points move the multiple.

The Valuation Problem You Shouldn't Ignore

Priced for continued execution. Waystar isn't a bargain-bin name. It trades at a healthy premium on forward sales, which means any earnings hiccup gets punished harder than a cheaper stock would be. You're paying for growth to continue, not for a turnaround.

The Iodine integration cost tail. Acquisitions this size come with an integration bill that keeps showing up in operating expenses for a few quarters. If margin expansion pauses because integration spend runs heavy, expect a re-rating lower before you give management the benefit of the doubt.

Sensitive to hospital IT spending cycles. When hospitals get spooked, IT budgets are one of the first things they slow-walk. That risk isn't in the stock right now.

What Needs to Happen Next

Q3 2026 earnings print. The next report is the near-term catalyst, expected in early November. Watch for continued guidance raises, NRR trending higher, and specific numbers on Iodine cross-sell attach rates.

New AI product traction. Management's been rolling out AI features across the platform. Watch for named customer wins or usage stats that show the AI tools aren't just marketing.

Larger enterprise wins. Waystar's been moving upmarket toward large health systems. Watch for a marquee integrated delivery network win in the next two quarters, which would materially shift the growth narrative.

Bear Case

Epic and Cerner competition. The two big EHR vendors are moving deeper into revenue cycle. If Epic bundles RCM more aggressively, that hits Waystar's pricing power in large health systems, and your thesis with it.

Integration execution risk. Iodine is a meaningful deal. If you see cross-sell stalling or churn spiking, the shine comes off the whole story fast.

Regulatory changes in healthcare payments. CMS rule changes and shifts in payer behavior can whipsaw the whole RCM sector. Waystar's navigated this before, but don't treat it as zero risk.

Macro pressure on hospital IT budgets. A softer economy or a policy-driven Medicaid squeeze could stretch out sales cycles, so track quarterly bookings and deal timing.

Action: Hedge with a broader healthcare IT name like Veeva Systems (NYSE: VEEV) or a diversified software ETF if you want the AI-in-healthcare exposure without single-name risk.

How I'd Frame a Position

Start small, add on pullbacks. This isn't a name you want to chase after a run. Build a starter position now and let the market give you better entries into Q3 earnings. Patience gets you filled.

Watch the reaction to Q3. If the print raises guidance again and NRR ticks up, that's your signal to add. Mixed print? Hold your position and wait for the next quarter.

If you already own it, sit tight. The Iodine cross-sell story is a multi-quarter unfold, not a single-catalyst trade. Trim only if the thesis breaks, meaning cross-sell stalls or margin expansion reverses.

The Setup Into Q3

Waystar is doing the boring, essential work of getting hospitals paid, and it's using AI to do it better than most of the competition. Q2 raised full-year guidance. The Iodine cross-sell is still ramping.

The stock isn't cheap, but the setup into Q3 earnings is one of the cleaner risk/reward pictures I've seen in healthcare tech this quarter. Build your position now, add on any weakness, and let the cross-sell numbers do the talking.

Setup Scorecard

Entry Zone: $22.50 to $24.00. WAY closed at $23.77, so you are buying inside the accumulation range rather than chasing.

Target: $30.00 over 12 months if Q3 confirms the cross-sell thesis, roughly 26% above the current price and still well under the $41.47 52-week high.

Stop Loss: $20.00. If WAY closes below that, the post-Q2 setup has broken and you should reassess rather than average down.

Catalyst Timeline: Q3 2026 earnings (early November), ongoing Iodine cross-sell metrics, any large IDN win announcements.

Confidence Level: Medium-High. The business is executing, but the valuation demands continued delivery. Trust-but-verify, not set-and-forget.

That's our coverage for today; thanks for reading! Reply to this email with feedback or any tech stocks you want me to check out.

Best Regards,
—Noah Zelvis
Tech Stock Insider